Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.85 USD
+1.06 (0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $126.90 +0.05 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVO 126.85 +1.06(0.84%)
Will NVO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Other News for NVO
What do weight-loss drugs mean for the diet industry?
ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
AstraZeneca: Strong In A Weak Market
Interesting NVO Put And Call Options For June 7th